» Articles » PMID: 33795750

Effective Rational Humanization of a PASylated Anti-galectin-3 Fab for the Sensitive PET Imaging of Thyroid Cancer in Vivo

Overview
Journal Sci Rep
Specialty Science
Date 2021 Apr 2
PMID 33795750
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

The lack of a non-invasive test for malignant thyroid nodules makes the diagnosis of thyroid cancer (TC) challenging. Human galectin-3 (hGal3) has emerged as a promising target for medical TC imaging and diagnosis because of its exclusive overexpression in malignant thyroid tissues. We previously developed a human-chimeric αhGal3 Fab fragment derived from the rat monoclonal antibody (mAb) M3/38 with optimized clearance characteristics using PASylation technology. Here, we describe the elucidation of the hGal3 epitope recognized by mAb M3/38, X-ray crystallographic analysis of its complex with the chimeric Fab and, based on the three-dimensional structure, the rational humanization of the Fab by CDR grafting. Four CDR-grafted versions were designed using structurally most closely related fully human immunoglobulin V/V regions of which one-employing the acceptor framework regions of the HIV-1 neutralizing human antibody m66-showed the highest antigen affinity. By introducing two additional back-mutations to the rodent donor sequence, an affinity toward hGal3 indistinguishable from the chimeric Fab was achieved (K = 0.34 ± 0.02 nM in SPR). The PASylated humanized Fab was site-specifically labelled with the fluorescent dye Cy7 and applied for the immuno-histochemical staining of human tissue sections representative for different TCs. The same protein was conjugated with the metal chelator Dfo, followed by radiolabelling with Zr(IV). The resulting protein tracer allowed the highly sensitive and specific PET/CT imaging of orthotopic tumors in mice, which was confirmed by quantitative analysis of radiotracer accumulation. Thus, the PASylated humanized αhGal3 Fab offers clinical potential for the diagnostic imaging of TC.

Citing Articles

Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape.

Scafetta G, DAlessandria C, Bartolazzi A J Exp Clin Cancer Res. 2024; 43(1):41.

PMID: 38317202 PMC: 10845537. DOI: 10.1186/s13046-024-02968-2.


ImmunoPET: Antibody-Based PET Imaging in Solid Tumors.

Manafi-Farid R, Ataeinia B, Ranjbar S, Jamshidi Araghi Z, Moradi M, Pirich C Front Med (Lausanne). 2022; 9:916693.

PMID: 35836956 PMC: 9273828. DOI: 10.3389/fmed.2022.916693.


Next-Generation Molecular Imaging of Thyroid Cancer.

Jin Y, Liu B, Younis M, Huang G, Liu J, Cai W Cancers (Basel). 2021; 13(13).

PMID: 34202358 PMC: 8268517. DOI: 10.3390/cancers13133188.

References
1.
Peplau E, De Rose F, Reder S, Mittelhauser M, Scafetta G, Schwaiger M . Development of a Chimeric Antigen-Binding Fragment Directed Against Human Galectin-3 and Validation as an Immuno-Positron Emission Tomography Tracer for the Sensitive Imaging of Thyroid Cancer. Thyroid. 2020; 30(9):1314-1326. DOI: 10.1089/thy.2019.0670. View

2.
Richter A, Knorr K, Schlapschy M, Robu S, Morath V, Mendler C . First In-Human Medical Imaging with a PASylated Zr-Labeled Anti-HER2 Fab-Fragment in a Patient with Metastatic Breast Cancer. Nucl Med Mol Imaging. 2020; 54(2):114-119. PMC: 7198682. DOI: 10.1007/s13139-020-00638-7. View

3.
Belfiore A, Giuffrida D, La Rosa G, Ippolito O, Russo G, Fiumara A . High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh). 1989; 121(2):197-202. DOI: 10.1530/acta.0.1210197. View

4.
Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

5.
Kogai T, Brent G . The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol Ther. 2012; 135(3):355-70. PMC: 3408573. DOI: 10.1016/j.pharmthera.2012.06.007. View